- Product Details
- Performance Data
- Reviews & Citations
- Resources

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced in human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
Recombinant Monoclonal
AM180
Human IgG1, Kappa
Human
Virus
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. Cross-reactivity with RBD of other coronaviruses has not been tested.
Application | Recommended Use / Performance |
ELISA | 0.2-2 μg/mL |
Protein A purified.
Please refer to the Certificate of Analysis (CoA).
Lyophilized
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Lyophilized product is shipped at ambient temperature.
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
Product Specific Notices: For research use only.